ArticleFrontiers in oncology2025
A retrospective analysis of inotuzumab ozogamicin usage in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real world outcomes with the use of Inotuzumab Ozogamicin in relapsed/refractory B cell acute lymphoblastic leukemia.Blood cancer journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The treatment of B-cell acute lymphoblastic leukemia (ALL) in India involves multi-agent chemotherapy and central nervous system (CNS) prophylaxis, but relapsed/refractory (R/R) B-cell ALL presents with high mortality and limited salvage options. Inotuzumab ozogamicin (InO), a monoclonal antibody targeting cluster of differentiation-22 (CD22) conjugated to calicheamicin, has improved outcomes for R/R B-cell ALL. A phase 3 multicenter trial (INO-VATE) in adult patients with CD22+ B-cell ALL has shown that InO significantly increases response rates and overall survival (OS) compared to standard treatments, with ongoing studies assessing its real-world effectiveness in India. Methodology: A multicentric, retrospective, observational study was conducted across five oncology centers in India to evaluate the effectiveness of InO in adult patients with R/R B-cell ALL. The study aimed to assess clinical outcomes, including the rate of complete remission (CR)/CR with incomplete hematologic recovery (CRi), minimal residual disease (MRD) negativity, duration of remission (DOR), OS, and the safety and tolerability of InO in real-world settings. Results: The medical records of adult patients (n = 32) aged >18 years with R/R B-cell ALL treated with InO between February 2017 and October 2022 were assessed. Among the total study participants, 59.4% (n = 19) achieved CR/CRi. Of these responders, MRD negativity was achieved in 94.7% (n = 18/19), and 68.4% (n = 13/19) achieved deep responses (MRD negative CR/CRi) after a median of two cycles of InO. The median DOR for those achieving CR/CRi was 6 months. Of the entire cohort, 34.4% (11/32) of the participants proceeded to hematopoietic stem cell transplantation (HSCT). The OS rates at 6 and 12 months in the entire cohort were 46.9% and 28.1%, respectively. The median relapse-free survival (RFS) among the responders was 7 months. Grade 3/4 treatment-related liver toxicity following InO initiation was reported in 37.5% of the participants. Myelosuppression-related adverse events were observed in 87.5% of the recipients. Conclusion: The real-world study (RWS) highlights the effectiveness of InO in achieving remission and MRD negativity in R/R B-cell ALL, although treatment-related toxicities remain a concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.